Roflumilast for the treatment of diabetes mellitus

1. A pharmaceutical composition comprising a pharmaceutical formulation including an amount of a compound of formula 1.1

or a pharmaceutically acceptable salt thereof and/or a compound of formula 1.2

or a pharmaceutically acceptable salt thereof, an amount of a dipeptidyl-peptidase IV inhibitor selected from the group consisting of SITAGLIPTIN, SAXAGLIPTIN, VILDAGLIPTIN, DENAGLIPTIN, P32/98, NVP-DPP-728 and the pharmaceutically acceptable salts of these compounds, wherein the first amount and the second amount together comprise an effective amount for the treatment of diabetes mellitus type 2 , and at least one pharmaceutically acceptable auxiliary.

2. The pharmaceutical composition according to claim 1 , wherein the dipeptidyl-peptidase IV inhibitor is selected from the group consisting of SITAGLIPTIN and the pharmaceutically acceptable salts thereof.